ADVANZ PHARMA (CXRXF) 6-K Concordia International Corp. Adds European Pharmaceutical Industry Expert to its Board of Directors

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of: October 2018

Commission File Number: 001- 37413

Concordia International Corp.

(Translation of registrant’s name into English)

5770 Hurontario Street, Suite 310,

Mississauga, Ontario, L5R 3G5

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F xForm 40-Fo

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

On October 29, 2018, Concordia International Corp. (the “Corporation”) announced the election of European pharmaceutical industry expert Maurice Chagnaud to its board of directors, effective November 1, 2018. In conjunction with this announcement the Corporation is filing the following exhibit:

Exhibit 99.1        Press release of Concordia International Corp., dated October 29, 2018.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Concordia International Corp.
By:	/s/ Adeel Ahmad
	Name:	Adeel Ahmad
	Title:	Chief Financial Officer

Date: October 29, 2018

EXHIBIT INDEX

Exhibit   No.	Description
99.1	Press release of Concordia International Corp., dated October 29, 2018.